A Phase II Trial of High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Metastatic Clear Cell Renal Cell Cancer (mRCC)
Latest Information Update: 11 Apr 2022
At a glance
- Drugs Aldesleukin (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 19 Feb 2022 Data from two studies (Phase I Safety Endpoint, NCT01896271& Phase II GI Toxicity Endpoint, NCT02353832) assessing he concordance of prospective genitourinary (GU) and gastrointestinal (GI) P-Tox and PR-QOL in men receiving SBRT for PCa, presented at the 2022 Genitourinary Cancers Symposium.
- 28 Jul 2021 Status changed from active, no longer recruiting to completed.
- 09 Mar 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2023.